At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.
About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most ...
Alternating platelet-rich plasma and intralesional corticosteroids was well tolerated in a pediatric Asian patient with ...
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs ...
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access ...
Sputum is considered a noninvasive marker of airway inflammation, and its color is an indicator of bronchiectasis disease ...
James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower ...
A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and ...
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.
T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results